DV
Dividend Vision

DNLI — Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI)

Total return is 13.8% over the past 8.7 years, 221.0 points behind SPY at 234.8%. Its deepest 1-year drawdown was 20.5%.

Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics for neurodegenerative and lysosomal storage diseases, with programs targeting conditions including Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and various rare genetic disorders. The company does not currently distribute dividends. Denali's pipeline includes multiple drug candidates at various development stages, appealing primarily to investors focused on long-term biotech innovation rather than current income generation.

DNLI key facts

Asset type
Stock
Asset class
Equity
Inception date
12/08/2017
Distribution frequency
None
Last close
$24.40
Market cap
$3,900,276,736
Average volume
879200.0
Beta
1.003
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.84